Product Description
Epirubicin is used in combination with other medications to treat breast cancer in patients who have had surgery to remove the tumor. Epirubicin is in a class of medications called anthracyclines. It works by slowing or stopping the growth of cancer cells in your body. (Sourced from: https://medlineplus.gov/druginfo/meds/a603003.html)
Mechanisms of Action: TOP2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Portugal, Romania, Russia, Singapore, Spain, Switzerland, Turkey, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 15
Highest Development Phases
Phase 3: Alveolar Rhabdomyosarcoma|Bladder Cancer|Breast Cancer|Clear Cell Sarcoma|Leiomyosarcoma|Liposarcoma|Sarcoma, Ewing|Triple Negative Breast Cancer
Phase 2: Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer|Hepatocellular Carcinoma|Inflammatory Breast Cancer|Muscle Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| STRASS 2 | P3 |
Unknown status |
Liposarcoma|Leiomyosarcoma |
2027-12-16 |
|
| VESTIGE | P2 |
Unknown status |
Esophageal Cancer|Adenocarcinoma|Gastrointestinal Cancer |
2026-12-06 |
|
| SJB-SQ-2023123 | P3 |
Recruiting |
Breast Cancer |
2026-06-30 |
|
| ROSCO V1.0, 15th October 2014 | P3 |
Unknown status |
Breast Cancer |
2025-05-26 |